Companies Immunovant
Immunovant (IMVT): executive pay, fiscal 2026
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Immunovant’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers94th pct.Of 16 peer CEOs
CEO pay, last three years
- $20,158,767FY2026
CEO total pay was $20,158,767 in fiscal 2026; the brief holds no earlier figure for this CEO.
FY2026: salary $636,618 · bonus $503,345 · stock awards $0 · option awards $19,010,639
Executives and directors
Peter Salzmann · Chief Executive OfficerEric Venker · CEOChristopher Van Tuyl · General CounselEva Renee Barnett · CFOJay Stout · CTOMelanie Gloria · COOMichael Geffner · Chief Medical OfficerTiago Girão · CFOAndrew Fromkin · Independent DirectorAtul Pande, M.D · Independent DirectorDouglas Hughes · Independent DirectorEric Venker, M.D., Pharm.D · DirectorFrank M. Torti, M.D · Chair of the BoardGeorge Migausky · Former director (through FY2026)Jacob Bauer · Independent DirectorRobert Susman · Independent Director
Frequently asked questions
Who was the highest-paid executive at Immunovant in fiscal 2026?
As disclosed, Eric Venker (Chief Executive Officer) was the highest-paid executive at Immunovant in fiscal 2026, with total compensation of $20,158,767.
How does Immunovant's chief executive pay compare to its disclosed peer group?
As disclosed, Eric Venker's total compensation ranked at the 94th percentile of Immunovant's disclosed peer group.
What is Immunovant's CEO-to-median employee pay ratio?
As disclosed, Immunovant's CEO-to-median employee pay ratio was 67:1.
How did shareholders vote on Immunovant's executive compensation?
As disclosed, 95.54% of shareholders supported Immunovant's executive compensation in the latest say-on-pay vote.
How much does Immunovant spend in total on board compensation for fiscal 2026?
As disclosed, Immunovant reported total board compensation of $5,490,052 for fiscal 2026.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Eric Venker | $636,618 | $503,345 | $0 | $19,010,639 | $0 | $0 | $8,165 | $20,158,767 |
| Chief Executive Officer | ||||||||
| Peter Salzmann | 39,614 | 0 | 8,287,949 | 6,269,395 | 0 | 0 | 737,642 | 15,334,600 |
| Former Chief Executive Officer | ||||||||
| Tiago Girão | 455,493 | 224,396 | 3,631,717 | 3,293,508 | 0 | 0 | 11,323 | 7,616,437 |
| Chief Financial Officer | ||||||||
| Michael Geffner | 345,521 | 0 | 2,564,119 | 2,145,870 | 0 | 0 | 198,579 | 5,254,089 |
| Former Chief Medical Officer | ||||||||
| Eva Renee Barnett | 26,250 | 0 | 1,350,946 | 1,462,825 | 0 | 0 | 387,431 | 3,227,452 |
| Former Chief Financial Officer | ||||||||
| Melanie Gloria | 495,000 | 245,025 | 1,157,951 | 1,150,095 | 0 | 0 | 19,041 | 3,067,112 |
| Chief Operating Officer | ||||||||
| Jay Stout | 495,000 | 245,025 | 1,157,951 | 1,150,095 | 0 | 0 | 17,650 | 3,065,721 |
| Chief Technology Officer | ||||||||
| Christopher Van Tuyl | 495,000 | 245,025 | 771,962 | 766,726 | 0 | 0 | 17,064 | 2,295,777 |
| Chief Legal Officer and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2026 total | FY2025 total | FY2024 total | Δ FY2025→2026 |
|---|---|---|---|---|
| Eric Venker | $20,158,767 | — | — | — |
| Peter Salzmann | 15,334,600 | 10,732,127 | 8,552,430 | ↑ +4,602,473 |
| Tiago Girão | 7,616,437 | — | — | — |
| Michael Geffner | 5,254,089 | 4,051,027 | — | ↑ +1,203,062 |
| Eva Renee Barnett | 3,227,452 | 3,970,734 | 3,338,969 | ↓ −743,282 |
| Melanie Gloria | 3,067,112 | 5,573,835 | — | ↓ −2,506,723 |
| Jay Stout | 3,065,721 | 3,979,353 | 4,039,880 | ↓ −913,632 |
| Christopher Van Tuyl | 2,295,777 | 5,948,339 | — | ↓ −3,652,562 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We have a "pay-for-performance"-focused executive compensation philosophy. Consistent with this philosophy, our Compensation Committee believes that compensation should be designed to optimize company performance to increase stockholder value.
| CEO STI target (% of salary) | 72% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2026
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Melanie Gloria | RSU | 2025-04-01 | — | — | 76,181 | — | $1,157,951 |
| Eva Renee Barnett | OPTION | 2025-04-20 | — | — | 478,563 | — | 121,046 |
| Jay Stout | RSU | 2025-04-01 | — | — | 76,181 | — | 1,157,951 |
| Michael Geffner | RSU | 2025-04-01 | — | — | 101,574 | — | 1,543,925 |
| Eric Venker | RSU | 2025-07-28 | — | 1,475,000 | — | — | 1,493,438 |
| Peter Salzmann | RSU | 2025-04-20 | — | — | 280,362 | — | 4,247,485 |
| Eva Renee Barnett | RSU | 2025-04-01 | — | — | 88,878 | — | 1,350,946 |
| Michael Geffner | OPTION | 2025-11-21 | — | — | 192,001 | — | 612,406 |
| Tiago Girão | RSU | 2025-04-21 | — | — | 31,708 | — | 318,348 |
| Tiago Girão | RSU | 2025-05-01 | — | — | 208,388 | — | 3,313,369 |
| Peter Salzmann | RSU | 2025-04-01 | — | — | 265,820 | — | 4,040,464 |
| Michael Geffner | RSU | 2025-11-21 | — | — | 44,765 | — | 1,020,194 |
| Peter Salzmann | OPTION | 2025-04-20 | — | — | 392,559 | — | 2,256,330 |
| Jay Stout | OPTION | 2025-04-01 | — | — | 107,297 | — | 1,150,095 |
| Christopher Van Tuyl | RSU | 2025-04-01 | — | — | 50,787 | — | 771,962 |
| Peter Salzmann | OPTION | 2025-04-01 | — | — | 374,395 | — | 4,013,065 |
| Michael Geffner | OPTION | 2025-04-01 | — | — | 143,063 | — | 1,533,464 |
| Eric Venker | OPTION | 2025-07-28 | — | — | 1,300,000 | — | 15,284,490 |
| Tiago Girão | OPTION | 2025-05-01 | — | — | 293,505 | — | 3,293,508 |
| Melanie Gloria | OPTION | 2025-04-01 | — | — | 107,297 | — | 1,150,095 |
| Eva Renee Barnett | OPTION | 2025-04-01 | — | — | 125,180 | — | 1,341,779 |
| Christopher Van Tuyl | OPTION | 2025-04-01 | — | — | 71,531 | — | 766,726 |
| Eric Venker | OPTION | 2025-07-28 | — | — | 189,900 | — | 2,232,711 |
| Jay Stout | PSU | 2025-08-27 | 70,000 | 140,000 | — | — | — |
| Melanie Gloria | PSU | 2025-08-27 | 160,000 | 320,000 | — | — | — |
| Michael Geffner | PSU | 2025-08-27 | 160,000 | 320,000 | — | — | — |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Melanie Gloria | $1,157,951 | $0 | $1,150,095 | 0.0% |
| Eva Renee Barnett | 1,350,946 | 0 | 1,462,825 | 0.0% |
| Jay Stout | 1,157,951 | 0 | 1,150,095 | 0.0% |
| Michael Geffner | 2,564,119 | 0 | 2,145,870 | 0.0% |
| Eric Venker | 1,493,438 | 0 | 17,517,201 | 0.0% |
| Peter Salzmann | 8,287,949 | 0 | 6,269,395 | 0.0% |
| Tiago Girão | 3,631,717 | 0 | 3,293,508 | 0.0% |
| Christopher Van Tuyl | 771,962 | 0 | 766,726 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2026
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Michael Geffner | RSU | 25,000 | — | $621,000 |
| Jay Stout | RSU | 30,926 | — | 768,202 |
| Michael Geffner | RSU | 30,926 | — | 768,202 |
| Jay Stout | RSU | 31,250 | — | 776,250 |
| Tiago Girão | RSU | 31,708 | — | 878,312 |
| Jay Stout | Option | 35,794 | 30.78 | — |
| Michael Geffner | Option | 35,794 | 30.78 | — |
| Michael Geffner | Option | 37,500 | 18.06 | — |
| Jay Stout | Option | 46,875 | 15.47 | — |
| Christopher Van Tuyl | RSU | 50,787 | — | 1,261,549 |
| Peter Salzmann | RSU | 56,408 | — | 1,401,175 |
| Jay Stout | PSU | 70,000 | — | 1,738,800 |
| Peter Salzmann | Option | 70,687 | 4.99 | — |
| Christopher Van Tuyl | Option | 71,531 | 15.2 | — |
| Melanie Gloria | RSU | 75,595 | — | 1,877,780 |
| Christopher Van Tuyl | RSU | 75,595 | — | 1,877,780 |
| Melanie Gloria | RSU | 76,181 | — | 1,892,336 |
| Jay Stout | RSU | 76,181 | — | 1,892,336 |
| Peter Salzmann | RSU | 76,198 | — | 1,892,758 |
| Peter Salzmann | Option | 85,742 | 14.7 | — |
| Peter Salzmann | RSU | 90,301 | — | 2,243,077 |
| Melanie Gloria | Option | 94,494 | 25.51 | — |
| Christopher Van Tuyl | Option | 94,494 | 27.63 | — |
| Michael Geffner | RSU | 101,574 | — | 2,523,098 |
| Peter Salzmann | Option | 104,515 | 30.78 | — |
| Melanie Gloria | Option | 107,297 | 15.2 | — |
| Jay Stout | Option | 107,297 | 15.2 | — |
| Michael Geffner | Option | 143,063 | 15.2 | — |
| Melanie Gloria | PSU | 160,000 | — | 3,974,400 |
| Michael Geffner | PSU | 160,000 | — | 3,974,400 |
| Tiago Girão | RSU | 208,388 | — | 5,176,358 |
| Peter Salzmann | RSU | 265,820 | — | 6,602,969 |
| Tiago Girão | Option | 293,505 | 15.9 | — |
| Peter Salzmann | Option | 374,395 | 15.2 | — |
| Eric Venker | Option | 1,475,000 | 14.46 | — |
| Eric Venker | Option | 1,489,900 | 16.76 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Frank M. Torti, M.DIndependent · Board Chair · Compensation | $92,500 | $3,030,348 | $971,380 | — | $0 | $4,094,228 |
| Jacob BauerIndependent · Audit (Chair) · Nominating/Governance | 71,497 | 397,754 | 392,824 | — | 0 | 862,075 |
| Robert SusmanIndependent · Audit · Compensation | 64,348 | 397,754 | 392,824 | — | 0 | 854,926 |
| George MigauskyIndependent · Not standing for re-election · Departed during FY | 3,306 | 491,307 | 175,042 | — | 0 | 669,655 |
| Andrew FromkinIndependent · Compensation (Chair) · Nominating/Governance | 72,734 | 246,058 | 78,559 | — | 0 | 397,351 |
| Douglas HughesIndependent · Audit · Compensation | 67,500 | 246,058 | 78,559 | — | 0 | 392,117 |
| Atul Pande, M.DIndependent · Nominating/Governance (Chair) | 60,233 | 246,058 | 78,559 | — | 0 | 384,850 |
| Eric Venker, M.D., Pharm.DEmployee director | 2,597 | 0 | 0 | — | 0 | 2,597 |
| Peter Salzmann, M.DEmployee director · Not standing for re-election · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $425,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 17,500 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2026 |
|---|---|
| Cash retainers and fees | $434,715 |
| Equity awards (grant-date value) | $5,055,337 |
| All other compensation | $0 |
| Total cost of the board | $5,490,052 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Immunovant as a peer
Companies that benchmark against IMVT
20 companies name IMVT as a compensation peer
- 89bio, Inc.ETNBFY2024
- Apogee Therapeutics, Inc.APGEFY2025
- Biohaven Ltd.BHVNFY2025
- Celldex Therapeutics, Inc.CLDXFY2025
- CG Oncology, Inc.CGONFY2025
- CYTOKINETICS INCCYTKFY2025
- Dyne Therapeutics, Inc.DYNFY2025
- IDEAYA Biosciences, Inc.IDYAFY2025
- Intellia Therapeutics, Inc.NTLAFY2025
- Kymera Therapeutics, Inc.KYMRFY2025
- Merus N.V.MRUSFY2024
- MoonLake ImmunotherapeuticsMLTXFY2025
- Nuvalent, Inc.NUVLFY2025
- Protagonist Therapeutics, IncPTGXFY2025
- SpringWorks Therapeutics, Inc.SWTXFY2024
- Vaxcyte, Inc.PCVXFY2025
- Vera Therapeutics, Inc.VERAFY2025
- Viridian Therapeutics, Inc.\DEVRDNFY2025
- Xenon Pharmaceuticals Inc.XENEFY2025
Each company listed discloses IMVT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named IMVT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2026
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ARWR Arrowhead PharmaceuticalsBHVN BiohavenCLDX Celldex TherapeuticsCRSP CRISPR Therapeutics AGCYTK CytokineticsDNLI Denali TherapeuticsKYMR Kymera TherapeuticsMDGL Madrigal PharmaceuticalsNUVL NuvalentACLX ArcellxBBIO BridgeBio PharmaXNCR XencorAPGE Apogee TherapeuticsXENE Xenon PharmaceuticalsVRDN Viridian TherapeuticsSWTX SpringWorks Therapeutics
Peer reciprocity
The companies Immunovant names as compensation peers that name it back in their own disclosed peer groups.
Biohaven (BHVN)88Celldex Therapeutics (CLDX)89Cytokinetics (CYTK)90Kymera Therapeutics (KYMR)91Nuvalent (NUVL)92Apogee Therapeutics (APGE)93Xenon Pharmaceuticals (XENE)94Viridian Therapeutics (VRDN)95SpringWorks Therapeutics (SWTX)96
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Arcellx | 2024 | Rami Elghandour | $653,288 | $9,342,069 | $10,850,151 | $0 | $21,402,668 |
| 2 | Immunovant | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 3 | Madrigal Pharmaceuticals | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 4 | SpringWorks Therapeutics | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 5 | BridgeBio Pharma | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 6 | Biohaven | 2025 | Vlad Coric | 920,400 | 2,202,480 | 9,900,043 | 0 | 13,500,438 |
| 7 | Cytokinetics | 2025 | Robert Blum | 853,069 | 5,150,019 | 5,095,918 | 772,715 | 11,881,456 |
| 8 | Nuvalent | 2025 | James Porter | 652,100 | 4,392,563 | 5,857,906 | 469,512 | 11,393,602 |
| 9 | Xenon Pharmaceuticals | 2025 | Ian Mortimer | 786,000 | 1,774,000 | 6,065,255 | 550,200 | 9,221,712 |
| 10 | Arrowhead Pharmaceuticals | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 11 | Kymera Therapeutics | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 12 | Crispr Therapeutics AG | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 13 | Viridian Therapeutics | 2025 | Stephen Mahoney | 700,000 | 1,058,098 | 4,381,713 | 630,000 | 6,776,249 |
| 14 | Xencor | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 15 | Celldex Therapeutics | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 16 | Denali Therapeutics | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 17 | Apogee Therapeutics | 2025 | Michael Henderson | 700,000 | 0 | 0 | 591,500 | 1,291,500 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Immunovant | 110% | not disclosed | No | Compensia |
| Apogee Therapeutics | not disclosed | Option 100 | not disclosed | Alpine Rewards |
| Arcellx | 140% | not disclosed | No | Meridian Compensation Partners |
| Arrowhead Pharmaceuticals | 125% | PRSU 70 · RSU 30 | not disclosed | Compensia |
| Biohaven | not disclosed | not disclosed | not disclosed | Aon |
| BridgeBio Pharma | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Celldex Therapeutics | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Crispr Therapeutics AG | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Cytokinetics | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| Denali Therapeutics | 145% | not disclosed | not disclosed | Alpine Rewards |
| Kymera Therapeutics | 125% | not disclosed | No | Alpine Rewards |
| Madrigal Pharmaceuticals | not disclosed | PSU 33.33 · RSU 33.33 · Option 33.33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia, Inc. |
| Nuvalent | 120% | not disclosed | No | Alpine Rewards |
| SpringWorks Therapeutics | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| Viridian Therapeutics | 150% | Options 75 · RSU 25 | not disclosed | Compensia |
| Xencor | 110% | Options 60 · RSU 40 | not disclosed | Aon |
| Xenon Pharmaceuticals | 100% | not disclosed | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-09-02 | 180,772,822 | 8,437,839 | 91,903 | 95.54% | Passed |
| 2025 | 2025-08-27 | 158,995,232 | 1,244,731 | 4,437 | 99.22% | Passed |
| 2024 | 2024-08-12 | 128,494,310 | 3,249,170 | 4,325 | 97.53% | Passed |
| 2023 | 2023-08-21 | 115,397,185 | 825,452 | 8,173 | 99.28% | Passed |
| 2022 | 2022-08-17 | 87,519,754 | 14,824,750 | 14,186 | 85.5% | Passed |
| 2021 | 2021-09-09 | 62,227,944 | 20,375,831 | 146,325 | 75.33% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-09-02 | 95.54%a |
| 2025 | 2025-08-27 | 99.22%b |
| 2024 | 2024-08-12 | 97.53%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total, and will have the same effect as "Against" votes.”.
c. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total, and will have the same effect as "Against" votes.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 67 : 1 |
|---|---|
| CEO total compensation | $20,224,962 |
| Median employee compensation | $303,366 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2026 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jay Stout | Chief Technology Officer | 2026-07-23 | D | 2,857 | $39 | $110,537 | Common | Form 4 ↗ |
| Tiago Girao | Chief Financial Officer | 2026-07-23 | D | 6,798 | 39 | 263,015 | Common | Form 4 ↗ |
| Atul Pande | Director | 2026-07-24 | A | 1,500 | 8 | 12,645 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-24 | — | 1,500 | — | — | 1 insider, 1 accrual row | ||
| Atul Pande | Director | 2026-07-24 | D | 1,500 | 40 | 59,700 | Common | Form 4 ↗ |
| Melanie Gloria | Chief Operating Officer | 2026-08-20 | D | 3,056 | 44 | 134,953 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-28 | — | 1,500 | — | — | 1 insider, 1 accrual row | ||
| Atul Pande | Director | 2026-08-28 | D | 1,500 | 43 | 64,905 | Common | Form 4 ↗ |
| Atul Pande | Director | 2026-08-28 | A | 1,500 | 8 | 12,645 | Common | Form 4 ↗ |
| Christopher Van Tuyl | Chief Legal Officer | 2026-09-23 | D | 2,846 | 36 | 103,481 | Common | Form 4 ↗ |
| Eric Venker | Director | 2026-10-01 | D | 85,886 | 34 | 2,890,064 | Common | Form 4 ↗ |
| Eric Venker | Director | 2026-10-01 | A | 92,187 | 14 | 1,333,024 | Common | Form 4 ↗ |
| Eric Venker | Director | 2026-10-01 | D | 92,187 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | Director | 2026-10-02 | D | 3,506 | 34 | 119,590 | Common | Form 4 ↗ |
| Jay Stout | Chief Technology Officer | 2026-10-07 | D | 2,213 | 32 | 70,949 | Common | Form 4 ↗ |
| Christopher Van Tuyl | Chief Legal Officer | 2026-10-07 | D | 1,327 | 32 | 42,544 | Common | Form 4 ↗ |
| Melanie Gloria | Chief Operating Officer | 2026-10-07 | D | 2,241 | 32 | 71,846 | Common | Form 4 ↗ |
| Jay Stout | Chief Technology Officer | 2026-10-07 | D | 1,596 | 32 | 51,168 | Common | Form 4 ↗ |
| Jay Stout | Chief Technology Officer | 2026-10-21 | D | 2,595 | 29 | 75,099 | Common | Form 4 ↗ |
| Tiago Girao | Chief Financial Officer | 2026-10-28 | D | 6,606 | 29 | 188,271 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 20 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jay Stout | Chief Technology Officer | 2026-07-23 | D | 2,857 | $39 | $110,537 | Common | Form 4 ↗ |
| Tiago Girao | Chief Financial Officer | 2026-07-23 | D | 6,798 | 39 | 263,015 | Common | Form 4 ↗ |
| Atul Pande | Director | 2026-07-24 | A | 1,500 | 8 | 12,645 | Common | Form 4 ↗ |
| Atul Pande | Director | 2026-07-24 | D | 1,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2026-07-24 | D | 1,500 | 40 | 59,700 | Common | Form 4 ↗ |
| Melanie Gloria | Chief Operating Officer | 2026-08-20 | D | 3,056 | 44 | 134,953 | Common | Form 4 ↗ |
| Atul Pande | Director | 2026-08-28 | D | 1,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2026-08-28 | D | 1,500 | 43 | 64,905 | Common | Form 4 ↗ |
| Atul Pande | Director | 2026-08-28 | A | 1,500 | 8 | 12,645 | Common | Form 4 ↗ |
| Christopher Van Tuyl | Chief Legal Officer | 2026-09-23 | D | 2,846 | 36 | 103,481 | Common | Form 4 ↗ |
| Eric Venker | Director | 2026-10-01 | D | 85,886 | 34 | 2,890,064 | Common | Form 4 ↗ |
| Eric Venker | Director | 2026-10-01 | A | 92,187 | 14 | 1,333,024 | Common | Form 4 ↗ |
| Eric Venker | Director | 2026-10-01 | D | 92,187 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | Director | 2026-10-02 | D | 3,506 | 34 | 119,590 | Common | Form 4 ↗ |
| Jay Stout | Chief Technology Officer | 2026-10-07 | D | 2,213 | 32 | 70,949 | Common | Form 4 ↗ |
| Christopher Van Tuyl | Chief Legal Officer | 2026-10-07 | D | 1,327 | 32 | 42,544 | Common | Form 4 ↗ |
| Melanie Gloria | Chief Operating Officer | 2026-10-07 | D | 2,241 | 32 | 71,846 | Common | Form 4 ↗ |
| Jay Stout | Chief Technology Officer | 2026-10-07 | D | 1,596 | 32 | 51,168 | Common | Form 4 ↗ |
| Jay Stout | Chief Technology Officer | 2026-10-21 | D | 2,595 | 29 | 75,099 | Common | Form 4 ↗ |
| Tiago Girao | Chief Financial Officer | 2026-10-28 | D | 6,606 | 29 | 188,271 | Common | Form 4 ↗ |
Sources (96 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Eric Venker. DEF 14A, filed 2026-07-22. Section “FY2026 Summary Compensation Table” · page 30. As printed: 20,158,767. View filing ↗
- Section 01, Peter Salzmann. DEF 14A, filed 2026-07-22. Section “FY2026 Summary Compensation Table”. As printed: 15,334,600. View filing ↗
- Section 01, Tiago Girão. DEF 14A, filed 2026-07-22. Section “FY2026 Summary Compensation Table”. As printed: 7,616,437. View filing ↗
- Section 01, Michael Geffner. DEF 14A, filed 2026-07-22. Section “FY2026 Summary Compensation Table”. As printed: 5,254,089. View filing ↗
- Section 01, Eva Renee Barnett. DEF 14A, filed 2026-07-22. Section “FY2026 Summary Compensation Table”. As printed: 3,227,452. View filing ↗
- Section 01, Melanie Gloria. DEF 14A, filed 2026-07-22. Section “FY2026 Summary Compensation Table”. As printed: 3,067,112. View filing ↗
- Section 01, Jay Stout. DEF 14A, filed 2026-07-22. Section “FY2026 Summary Compensation Table”. As printed: 3,065,721. View filing ↗
- Section 01, Christopher Van Tuyl. DEF 14A, filed 2026-07-22. Section “FY2026 Summary Compensation Table”. As printed: 2,295,777. View filing ↗
- Section 03, Melanie Gloria RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Eva Renee Barnett OPTION. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jay Stout RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Geffner RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Eric Venker RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Peter Salzmann RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Eva Renee Barnett RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Geffner OPTION. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Tiago Girão RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Tiago Girão RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Peter Salzmann RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Geffner RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Peter Salzmann OPTION. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jay Stout OPTION. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Van Tuyl RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Peter Salzmann OPTION. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Geffner OPTION. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Eric Venker OPTION. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Tiago Girão OPTION. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Melanie Gloria OPTION. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Eva Renee Barnett OPTION. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Van Tuyl OPTION. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Eric Venker OPTION. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jay Stout PSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Melanie Gloria PSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Geffner PSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-07-22. Section “CEO Pay Ratio”. As printed: 67 : 1. View filing ↗
- Section 08, Frank M. Torti, M.D. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 4,094,228. View filing ↗
- Section 08, Jacob Bauer. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 862,075. View filing ↗
- Section 08, Robert Susman. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 854,926. View filing ↗
- Section 08, George Migausky. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 669,655. View filing ↗
- Section 08, Andrew Fromkin. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 397,351. View filing ↗
- Section 08, Douglas Hughes. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 392,117. View filing ↗
- Section 08, Atul Pande, M.D. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 384,850. View filing ↗
- Section 08, Eric Venker, M.D., Pharm.D. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 2,597. View filing ↗
- Section 08, Peter Salzmann, M.D. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Jay Stout 2026-07-23. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tiago Girao 2026-07-23. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atul Pande 2026-07-24. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atul Pande 2026-07-24. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atul Pande 2026-07-24. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Melanie Gloria 2026-08-20. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atul Pande 2026-08-28. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atul Pande 2026-08-28. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atul Pande 2026-08-28. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Van Tuyl 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Venker 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Venker 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Venker 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Venker 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jay Stout 2026-10-07. Form 4, filed 2026-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Van Tuyl 2026-10-07. Form 4, filed 2026-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Melanie Gloria 2026-10-07. Form 4, filed 2026-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jay Stout 2026-10-07. Form 4, filed 2026-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jay Stout 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tiago Girao 2026-10-28. Form 4, filed 2026-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-09-03. Item 5.07 · say-on-pay result. As reported: 95.54% (votes for as printed: 180,772,822). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-08-28. Item 5.07 · say-on-pay result. As reported: 99.22% (votes for as printed: 158,995,232). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-08-13. Item 5.07 · say-on-pay result. As reported: 97.53% (votes for as printed: 128,494,310). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 434,715 + equity 5,055,337 + all other 0 = 5,490,052, summed across the director compensation table rows.
- Arcellx, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Arcellx's own proxy. As printed: 21,402,668. View filing ↗
- Immunovant (subject), Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Immunovant's own proxy. As printed: 20,158,767. View filing ↗
- Madrigal Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals's own proxy. As printed: 19,206,341. View filing ↗
- SpringWorks Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics's own proxy. As printed: 16,153,317. View filing ↗
- BridgeBio Pharma, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. View filing ↗
- Biohaven, Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in Biohaven's own proxy. As printed: 13,500,438. View filing ↗
- Cytokinetics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Cytokinetics's own proxy. As printed: 11,881,456. View filing ↗
- Nuvalent, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Nuvalent's own proxy. As printed: 11,393,602. View filing ↗
- Xenon Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Xenon Pharmaceuticals's own proxy. As printed: 9,221,712. View filing ↗
- Arrowhead Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-01-27. CEO total compensation as printed in Arrowhead Pharmaceuticals's own proxy. As printed: 9,029,861. View filing ↗
- Kymera Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. View filing ↗
- Crispr Therapeutics AG, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Crispr Therapeutics AG's own proxy. As printed: 7,678,477. View filing ↗
- Viridian Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Viridian Therapeutics's own proxy. As printed: 6,776,249. View filing ↗
- Xencor, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Xencor's own proxy. As printed: 5,521,205. View filing ↗
- Celldex Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Celldex Therapeutics's own proxy. As printed: 5,366,709. View filing ↗
- Denali Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. View filing ↗
- Apogee Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Apogee Therapeutics's own proxy. As printed: 1,291,500. View filing ↗
- Section 10a, Biohaven reciprocity. DEF 14A. Biohaven names Immunovant in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Celldex Therapeutics reciprocity. DEF 14A. Celldex Therapeutics names Immunovant in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Cytokinetics reciprocity. DEF 14A. Cytokinetics names Immunovant in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Kymera Therapeutics reciprocity. DEF 14A. Kymera Therapeutics names Immunovant in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Nuvalent reciprocity. DEF 14A. Nuvalent names Immunovant in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Apogee Therapeutics reciprocity. DEF 14A. Apogee Therapeutics names Immunovant in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Xenon Pharmaceuticals reciprocity. DEF 14A. Xenon Pharmaceuticals names Immunovant in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Viridian Therapeutics reciprocity. DEF 14A. Viridian Therapeutics names Immunovant in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, SpringWorks Therapeutics reciprocity. DEF 14A. SpringWorks Therapeutics names Immunovant in its own disclosed peer group (read from its most recent proxy). View filing ↗